Pfizer Earnings Call, First Quarter 2008
The pharmaceutical company reported net income of $2.8 billion or 41 cents a share, down 18% from $3.4 billion or 48 cents a share from the prior year due to lower revenues due to the U.S. losses of exclusivity discussed above and increased in-process research and development expenses associated with acquisitions, primarily CovX and Coley Pharmaceutical Group, Inc., which were partially offset by lower expenses related to our cost-reduction initiatives and foreign exchange.

FAA bans Pfizer's Chantix for flight personnel
BOSTON (MarketWatch) -- In an unusual move, the Federal Aviation Administration on Wednesday banned the use of the Pfizer smoking-cessation product Chantix by airline pilots and air-traffic controllers, citing concerns that the drug could contribute to accidents.